1. Home
  2. TACT vs MAIA Comparison

TACT vs MAIA Comparison

Compare TACT & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TransAct Technologies Incorporated

TACT

TransAct Technologies Incorporated

HOLD

Current Price

$4.47

Market Cap

46.1M

Sector

Technology

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.18

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TACT
MAIA
Founded
1996
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
46.1M
44.9M
IPO Year
1996
2022

Fundamental Metrics

Financial Performance
Metric
TACT
MAIA
Price
$4.47
$1.18
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$5.00
N/A
AVG Volume (30 Days)
49.1K
417.1K
Earning Date
11-10-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$50,258,000.00
N/A
Revenue This Year
$21.67
N/A
Revenue Next Year
$7.63
N/A
P/E Ratio
N/A
N/A
Revenue Growth
8.27
N/A
52 Week Low
$3.12
$0.87
52 Week High
$5.70
$2.74

Technical Indicators

Market Signals
Indicator
TACT
MAIA
Relative Strength Index (RSI) 51.95 50.83
Support Level $4.30 $0.87
Resistance Level $4.75 $1.46
Average True Range (ATR) 0.25 0.11
MACD 0.05 0.04
Stochastic Oscillator 64.71 47.46

Price Performance

Historical Comparison
TACT
MAIA

About TACT TransAct Technologies Incorporated

Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Share on Social Networks: